MA43106A - Traitement de l'oligo-ovulation associée à la stéatose hepatique - Google Patents

Traitement de l'oligo-ovulation associée à la stéatose hepatique

Info

Publication number
MA43106A
MA43106A MA043106A MA43106A MA43106A MA 43106 A MA43106 A MA 43106A MA 043106 A MA043106 A MA 043106A MA 43106 A MA43106 A MA 43106A MA 43106 A MA43106 A MA 43106A
Authority
MA
Morocco
Prior art keywords
oligo
treatment
hepatic steatosis
ovulation
ovulation associated
Prior art date
Application number
MA043106A
Other languages
English (en)
Other versions
MA43106B1 (fr
Inventor
Zegher Francis De
Lourdes Ibáñez
Original Assignee
Sant Joan De Deu Hospital
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sant Joan De Deu Hospital, Univ Leuven Kath filed Critical Sant Joan De Deu Hospital
Publication of MA43106A publication Critical patent/MA43106A/fr
Publication of MA43106B1 publication Critical patent/MA43106B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA43106A 2015-10-27 2016-10-27 Traitement de l'oligo-ovulation associée à la stéatose hepatique MA43106B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518979.8A GB201518979D0 (en) 2015-10-27 2015-10-27 Treatment of hepatic steatosis related oligo-ovulation
PCT/EP2016/075953 WO2017072243A1 (fr) 2015-10-27 2016-10-27 Traitement de l'oligo-ovulation associée à la stéatose hépatique

Publications (2)

Publication Number Publication Date
MA43106A true MA43106A (fr) 2021-05-05
MA43106B1 MA43106B1 (fr) 2021-09-30

Family

ID=55130283

Family Applications (2)

Application Number Title Priority Date Filing Date
MA43106A MA43106B1 (fr) 2015-10-27 2016-10-27 Traitement de l'oligo-ovulation associée à la stéatose hepatique
MA054412A MA54412A (fr) 2015-10-27 2016-10-27 Traitement d'excès de graisse hépatique et/ou viscérale

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA054412A MA54412A (fr) 2015-10-27 2016-10-27 Traitement d'excès de graisse hépatique et/ou viscérale

Country Status (24)

Country Link
US (2) US20190060328A1 (fr)
EP (2) EP3368044B1 (fr)
JP (2) JP6999903B2 (fr)
KR (1) KR102608158B1 (fr)
CN (2) CN108778285A (fr)
AR (1) AR106505A1 (fr)
AU (1) AU2016344737C1 (fr)
BR (1) BR112018008496A2 (fr)
CA (1) CA3003076C (fr)
DK (1) DK3368044T3 (fr)
ES (1) ES2883282T3 (fr)
GB (1) GB201518979D0 (fr)
HU (1) HUE055778T2 (fr)
IL (1) IL258876B (fr)
LT (1) LT3368044T (fr)
MA (2) MA43106B1 (fr)
MX (2) MX384040B (fr)
PL (1) PL3368044T3 (fr)
RS (1) RS62764B1 (fr)
RU (1) RU2745606C2 (fr)
SI (1) SI3368044T1 (fr)
TW (1) TWI791420B (fr)
UY (1) UY36967A (fr)
WO (1) WO2017072243A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020012336A2 (pt) 2017-12-19 2021-03-30 Akouos, Inc. Administração de anticorpos terapêuticos mediada por aav para o ouvido interno
JP2021533109A (ja) * 2018-08-02 2021-12-02 オスピタル サン ジュアン ダ デウ 多嚢胞性卵巣症候群の治療に有用な医薬品有効成分の三重組合せの即時放出製剤
EP3842803A1 (fr) * 2019-12-23 2021-06-30 Katholieke Universiteit Leuven Cxcl14 dans le syndrome des ovaires polykystiques
AR122078A1 (es) 2020-05-13 2022-08-10 Akouos Inc Composiciones y métodos para tratar la pérdida auditiva asociada a slc26a4
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
KR20230127263A (ko) 2020-12-29 2023-08-31 아카우오스, 인크. Clrn1-연관된 청력손실 및/또는 시력손실을 치료하기위한 조성물 및 방법
EP4473011A1 (fr) 2022-02-02 2024-12-11 Akouos, Inc. Constructions d'anticorps anti-vegf et méthodes associées pour le traitement de symptômes associés au schwannome vestibulaire

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
AU2001239826B2 (en) * 2000-02-23 2006-06-15 Orentreich Foundation For The Advancement Of Science, Inc. Methods and compositions for the treatment of alopecia and other disorders of the pilosebaceous apparatus
GB0106565D0 (en) * 2001-03-16 2001-05-09 Leuven K U Res & Dev Growth hormone treatment
GB0108863D0 (en) * 2001-04-10 2001-05-30 Leuven K U Res & Dev Combinational therapy
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
AU2003256988A1 (en) * 2002-12-11 2004-06-30 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
GB0702537D0 (en) * 2007-02-12 2007-03-21 Leuven K U Res & Dev Treatment for excessive adiposity
US10474539B1 (en) * 2015-12-18 2019-11-12 EMC IP Holding Company LLC Browsing federated backups
JP2021533109A (ja) * 2018-08-02 2021-12-02 オスピタル サン ジュアン ダ デウ 多嚢胞性卵巣症候群の治療に有用な医薬品有効成分の三重組合せの即時放出製剤

Also Published As

Publication number Publication date
MX384040B (es) 2025-03-14
ES2883282T3 (es) 2021-12-07
HUE055778T2 (hu) 2021-12-28
JP2022009374A (ja) 2022-01-14
SI3368044T1 (sl) 2022-05-31
UY36967A (es) 2017-05-31
MA43106B1 (fr) 2021-09-30
IL258876B (en) 2022-03-01
EP3368044B1 (fr) 2021-06-09
JP6999903B2 (ja) 2022-02-04
US20240000804A1 (en) 2024-01-04
BR112018008496A2 (pt) 2018-10-23
TW201720432A (zh) 2017-06-16
WO2017072243A9 (fr) 2018-07-26
EP3368044A1 (fr) 2018-09-05
AR106505A1 (es) 2018-01-24
CN108778285A (zh) 2018-11-09
CA3003076A1 (fr) 2017-05-04
AU2016344737A9 (en) 2018-08-09
RU2018119146A (ru) 2019-11-28
MA54412A (fr) 2021-11-10
AU2016344737A1 (en) 2018-05-17
KR20180098234A (ko) 2018-09-03
CN117379440A (zh) 2024-01-12
US20190060328A1 (en) 2019-02-28
CA3003076C (fr) 2023-12-05
DK3368044T3 (da) 2021-09-13
TWI791420B (zh) 2023-02-11
KR102608158B1 (ko) 2023-11-29
GB201518979D0 (en) 2015-12-09
AU2016344737C1 (en) 2021-10-07
AU2016344737B2 (en) 2021-07-08
IL258876A (en) 2018-06-28
LT3368044T (lt) 2021-10-25
MX2021007976A (es) 2021-08-16
WO2017072243A8 (fr) 2018-03-22
PL3368044T3 (pl) 2021-12-20
RU2745606C2 (ru) 2021-03-29
EP3892281A2 (fr) 2021-10-13
JP2019501113A (ja) 2019-01-17
RU2018119146A3 (fr) 2020-02-25
WO2017072243A1 (fr) 2017-05-04
MX2018005252A (es) 2018-09-18
RS62764B1 (sr) 2022-01-31
EP3892281A3 (fr) 2021-11-10

Similar Documents

Publication Publication Date Title
MA45192A (fr) Traitement d'association
EP3370721A4 (fr) Traitement de l'ostéoarthrite
EP3464313A4 (fr) Nucléotides modifiés 5 '-cyclo-phosphonate
MA46180A (fr) Analogues de l'amyline
SI3785717T1 (sl) Postopki za zdravljenje okužb s Coronaviridae
PT3368534T (pt) Ditosilato de valbenazina e polimorfos do mesmo
EP3360554A4 (fr) Agent anti-virus de l'hépatite b
EP3325963A4 (fr) Amélioration de l'estimation de globules
ME03070B (fr) Méthodes pour le traitement d'infections virales à filoviridae
HRP20251450T1 (hr) Beta-d-2'-dezoksi-2'alfa-fluoro-2'-beta-c-supstituirani-2-modificirani-n6-supstituirani purinski nukleotidi za liječenje hcv
EP3261641A4 (fr) Traitement de la pancréatite
FR3036037B1 (fr) Harnais d'encordement perfectionne
EP3340971A4 (fr) Méthodes de traitement de syndrome de lennox-gastaut à l'aide de fenfluramine
EP3443094A4 (fr) Procédés de réduction de l'expression de c9orf72
MA46788A (fr) Traitement de la fibrose
EP3250367A4 (fr) Étalonnage d'agent
EP3375108A4 (fr) Traitement dewlan
EP3347334A4 (fr) Déshydrohalogénation d'hydrochlorofluorocarbones
LT3307267T (lt) Išsėtinės sklerozės gydymas
EP3347032A4 (fr) Traitement de l'ascite
HUE055778T2 (hu) Oligo-ovulációval összefüggõ májzsírosodás kezelése
DK3706699T3 (da) Badekonstruktion
EP3328384A4 (fr) Traitement de la fibrose
EP3309165A4 (fr) Agent de traitement de surface
MA41782A (fr) Traitement de patients atteints de diabète de type 2